Search
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational[A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis.
Eladocagene exuparvovec
go.drugbank.com/drugs/DB16780ApprovedInvestigational[A253687] It was subsequently approved by the FDA in November 2024.[L51898,L51893] … Eladocagene exuparvovec is infused directly into the brain (putamen) by bilateral intraputaminal infusion in one surgical session.
Oxybenzone
go.drugbank.com/drugs/DB01428ApprovedOxybenzone is an organic compound used in sunscreens. It is a derivative of benzophenone. It forms colorless crystals that are readily soluble in most organic solvents. It is used as an ingredient in sunscreen and other cosmetics because...
Mixtures: Chopper Chap Lip Balm, Chap - Grip SPF 15Macitentan
go.drugbank.com/drugs/DB08932ApprovedInvestigational[L39105] It was subsequently approved by the FDA in March 2024.[L50622] … [L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity.
Deuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigational[A264108, A264113, A264123] Deuruxolitinib works to block the inflammatory responses caused by JAKs.[L51068] … [A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata.
Dihydroergocristine
go.drugbank.com/drugs/DB13345Approved[L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.
Lomitapide
go.drugbank.com/drugs/DB08827Approved[A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446] … A7367] It was developed to address the significant unmet medical need in patients with homozygous familial hypercholesterolemia (HoFH)—an ultra-rare and life-threatening genetic disorder characterized by
Recombinant alpha 1-antitrypsin
go.drugbank.com/drugs/DB05481InvestigationalRecombinant alpha 1-antitrypsin (rAAT) is produced from yeast, which unlike commercially available forms of plasma-derived AAT, eliminates the risk associated with blood-borne infectious agents and allows … Alpha 1-antitrypsin is a glycoprotein primarily produced by hepatocytes, and to a lesser extent, immune system cells.
Samidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigationalby Alkermes Inc. … [A235638, A235643] Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™
Pancrelipase
go.drugbank.com/drugs/DB00085ApprovedInvestigational[L2509] The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.